Here's Why Abeona Therapeutics Popped Higher Today
Key Points
Abeona stock surged over 25% after reporting strong earnings and receiving positive updates on Zevaskyn.
Major insurers now cover Zevaskyn, and patient identification is progressing.
- 10 stocks we like better than Abeona Therapeutics ›
Abeona Therapeutics (NASDAQ: ABEO) stock soared by more than 25% as of 10 a.m. today. The reason for the surging share price is a strong set of third-quarter earnings and a very positive update on its Recessive Dystrophic Epidermolysis Bullosa (RDEB) treatment, Zevaskyn.
Treatment for a rare disease
RDEB is a very rare and inherited skin disorder that leaves highly sensitive skin, which is easily torn or blistered. Academic studies have estimated its incidence at 3.05 per million births, and prevalence at 1.35 per million. Prevalence is significantly lower than incidence because many sufferers die at an early age due to complications caused by this severe disorder.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Zevaskyn is a gene therapy made from a patient's own skin, which has been modified to carry a healthy copy of a gene responsible for producing collagen, and then applied to the patient's wounds.
Based on the U.S. population of approximately 340.1 million and the prevalence rate, there are approximately 460 potential patients in the U.S. who could benefit from Zevaskyn. This calculation highlights the importance of raising awareness about the treatment and obtaining coverage from commercial healthcare plans.
The good news is that Abeona had positive updates on both.
Patients identified and health coverage
First, management said 30 patients had now been identified at qualifying treatment centers, with 12 patients "in the process of scheduling treatments" from the initial "more than a dozen" identified. This implies a strong willingness among RDEB patients to try treatment.
Second, management also noted, "Policies covering Zevaskyn have been published by all major commercial payers, including UnitedHealthcare, Cigna, Aetna, Anthem, and most Blue Cross Blue Shield plans."
Image source: Getty Images.
These developments are so positive that the market chose to overlook the one-quarter delay in the start of treatments due to a now-resolved issue.
All told, Abeona looks set to start treating patients this quarter, with significant growth in revenue to come in 2026.
Should you invest $1,000 in Abeona Therapeutics right now?
Before you buy stock in Abeona Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Abeona Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $612,872!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,184,044!*
Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 10, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.
Recommended Articles
